Currently, the FDA guidelines state that to be considered for a GLP-1 agonist, individuals must have: A BMI of 30 or greater OR A BMI of 27 or greater with at least one weight-related comorbidity (i.e
Onteniente B, Geffard M, Campistron G, Calas A (1987)
The FDA clears specific containers for medical waste disposal based on five criteria: puncture-resistant walls, leak-proof bottom and sides, a tight-fitting puncture-resistant lid, clear labeling, and an upright stable base
This guide covers everything you need to know about Ipamorelin: how it works, its benefits, dosing protocols, side effects, and how it compares to other growth hormone peptides
For a broader comparison of weight loss peptides, see our best peptides for weight loss guide